‘Overpriced’ Antifungal Drug Seized In Kothagudem

Hyderabad: As part of stepped-up surveillance against overcharging of essential medicines, the Drugs Control Administration (DCA), Telangana, officials have seized ‘overpriced’ antifungal drug ‘GRISOLAB-250’ Griseofulvin tablets-250 mg during a surprise check in Kothagudem on Tuesday.

The worth of the stock seized during the raid is ₹4,095, according to a press release. The seized product, manufactured by Laborate Pharmaceuticals India Ltd, Himachal Pradesh, and marketed by Gpp Axalade, Salwan, Haryana, bears MRP as ₹65 for 10 tablets on the label of the product, which is a violation of Drugs (Prices Control) Order, 2013, the press release added. The ceiling price fixed by the Central government for the product ‘Griseofulvin tablets-250 mg’ is ₹17.7 for 10 tablets. Hence, the MRP i.e., including GST 12% should not be more than ₹19.83 for 10 tablets.

However, the pharmaceutical firm ‘overpriced’ the product. A strip of tablets has been charged excess of ₹45.17 per 10 tablets. Further investigation into the matter is underway and action will be taken against all the offenders as per the law, the DCA officials said.

In a separate incident, the DCA sleuths raided a medical shop named ‘Amaan Medical and General Stores’ allegedly operating without drug licence at Jaklair village in Narayanpet district. The officials seized an unauthorised stock of medicines including antibiotic injections, IV fluids, analgesics, antihypersensitive drugs and cough syrups worth ₹ 1.20 lakh. Further investigation is in progress.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’